FR2755975B1 - Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies - Google Patents

Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies

Info

Publication number
FR2755975B1
FR2755975B1 FR9613969A FR9613969A FR2755975B1 FR 2755975 B1 FR2755975 B1 FR 2755975B1 FR 9613969 A FR9613969 A FR 9613969A FR 9613969 A FR9613969 A FR 9613969A FR 2755975 B1 FR2755975 B1 FR 2755975B1
Authority
FR
France
Prior art keywords
dyslipoproteinemia
treatment
related conditions
recombinant viruses
viruses useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9613969A
Other languages
English (en)
Other versions
FR2755975A1 (fr
Inventor
Robert Tonkia
Sandrine Seguret
Patrick Benoit
Didier Rouy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9613969A priority Critical patent/FR2755975B1/fr
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Priority to IL12982397A priority patent/IL129823A0/xx
Priority to CA002271437A priority patent/CA2271437A1/fr
Priority to SK634-99A priority patent/SK63499A3/sk
Priority to AU51252/98A priority patent/AU721654B2/en
Priority to EP97945922A priority patent/EP0941355A1/fr
Priority to ZA9710271A priority patent/ZA9710271B/xx
Priority to JP52326398A priority patent/JP2001506488A/ja
Priority to HU9904500A priority patent/HUP9904500A3/hu
Priority to KR1019990704322A priority patent/KR20000053320A/ko
Priority to CZ991703A priority patent/CZ170399A3/cs
Priority to BR9712957-7A priority patent/BR9712957A/pt
Priority to PCT/FR1997/002043 priority patent/WO1998022606A1/fr
Publication of FR2755975A1 publication Critical patent/FR2755975A1/fr
Application granted granted Critical
Publication of FR2755975B1 publication Critical patent/FR2755975B1/fr
Priority to NO992260A priority patent/NO992260L/no
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
FR9613969A 1996-11-15 1996-11-15 Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies Expired - Fee Related FR2755975B1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FR9613969A FR2755975B1 (fr) 1996-11-15 1996-11-15 Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
CZ991703A CZ170399A3 (cs) 1996-11-15 1997-11-13 Rekombinantní bicistronový adenovirus vhodný pro léčení dyslipoproteinémií, jeho použití a farmaceutický přípravek obsahující takový virus
SK634-99A SK63499A3 (en) 1996-11-15 1997-11-13 Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia
AU51252/98A AU721654B2 (en) 1996-11-15 1997-11-13 Bicistronic recombinant viruses useful for the treatment of dyslipoproteinemia-related pathologies
EP97945922A EP0941355A1 (fr) 1996-11-15 1997-11-13 Adenovirus recombinants bicistroniques pour le traitement de pathologies liees aux dyslipoproteinemies
ZA9710271A ZA9710271B (en) 1996-11-15 1997-11-13 Bicistronic recombinant viruses useful for the treatment of dyslipoproteinemia-related pathologies
JP52326398A JP2001506488A (ja) 1996-11-15 1997-11-13 リポタンパク質異常血症に関連する病的症状を治療するための組換えバイシストロンアデノウイルス
HU9904500A HUP9904500A3 (en) 1996-11-15 1997-11-13 Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia
IL12982397A IL129823A0 (en) 1996-11-15 1997-11-13 Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia
CA002271437A CA2271437A1 (fr) 1996-11-15 1997-11-13 Adenovirus recombinants bicistroniques pour le traitement de pathologies liees aux dyslipoproteinemies
BR9712957-7A BR9712957A (pt) 1996-11-15 1997-11-13 Vìrus a adenovìrus recombinantes defeituosos, plasmìdeos procariótico e bifuncional, célula procariótica, utilização de um vìrus recombinante defeitusos, e, composição farmacêutica
PCT/FR1997/002043 WO1998022606A1 (fr) 1996-11-15 1997-11-13 Adenovirus recombinants bicistroniques pour le traitement de pathologies liees aux dyslipoproteinemies
KR1019990704322A KR20000053320A (ko) 1996-11-15 1997-11-13 이상지단백혈증과 결부된 병리학적 증상 치료용 재조합비시스트론 아데노바이러스
NO992260A NO992260L (no) 1996-11-15 1999-05-10 Rekombinant bicistronadenovirus for behandling av patologiske tilstander forbundet med dyslipoproteinemi

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9613969A FR2755975B1 (fr) 1996-11-15 1996-11-15 Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies

Publications (2)

Publication Number Publication Date
FR2755975A1 FR2755975A1 (fr) 1998-05-22
FR2755975B1 true FR2755975B1 (fr) 1999-05-07

Family

ID=9497670

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9613969A Expired - Fee Related FR2755975B1 (fr) 1996-11-15 1996-11-15 Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies

Country Status (14)

Country Link
EP (1) EP0941355A1 (fr)
JP (1) JP2001506488A (fr)
KR (1) KR20000053320A (fr)
AU (1) AU721654B2 (fr)
BR (1) BR9712957A (fr)
CA (1) CA2271437A1 (fr)
CZ (1) CZ170399A3 (fr)
FR (1) FR2755975B1 (fr)
HU (1) HUP9904500A3 (fr)
IL (1) IL129823A0 (fr)
NO (1) NO992260L (fr)
SK (1) SK63499A3 (fr)
WO (1) WO1998022606A1 (fr)
ZA (1) ZA9710271B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047690A2 (fr) * 1998-03-16 1999-09-23 Introgen Therapeutics, Inc. Vecteurs multigenes
AU7769800A (en) * 1999-08-10 2001-03-05 Develogen Ag Fur Entwicklungsbiologische Forschung Gene transfer combination vectors, method for the production and utilization thereof
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
AU4764801A (en) * 2000-03-24 2001-10-08 Calydon Inc Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
EP1392504A4 (fr) 2001-04-02 2008-03-05 Agilent Technologies Inc Surfaces de detecteur permettant de detecter des substances a analyser
RU2016119726A (ru) * 2011-08-08 2018-11-02 Апталис Фарма Лтд. Способ проведения теста на растворение твердых композиций, содержащих пищеварительные ферменты
WO2021031551A1 (fr) * 2019-08-19 2021-02-25 南京诺惟生物科技有限公司 Adénovirus oncolytique réplicatif pour réguler le métabolisme lipidique et son utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3378962B2 (ja) * 1991-08-07 2003-02-17 アンダースン，ダブリュー．，フレンチ 内部リボソームエントリー部位を含むレトロウイルスベクター
GB9125896D0 (en) * 1991-12-05 1992-02-05 Almond Jeffrey W Bicistronic viruses
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US6001557A (en) * 1994-10-28 1999-12-14 The Trustees Of The University Of Pennsylvania Adenovirus and methods of use thereof
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique

Also Published As

Publication number Publication date
AU5125298A (en) 1998-06-10
WO1998022606A1 (fr) 1998-05-28
CZ170399A3 (cs) 1999-08-11
ZA9710271B (en) 1998-08-21
CA2271437A1 (fr) 1998-05-28
EP0941355A1 (fr) 1999-09-15
AU721654B2 (en) 2000-07-13
NO992260D0 (no) 1999-05-10
HUP9904500A2 (hu) 2000-05-28
BR9712957A (pt) 2000-02-01
IL129823A0 (en) 2000-02-29
NO992260L (no) 1999-05-10
KR20000053320A (ko) 2000-08-25
SK63499A3 (en) 2000-05-16
FR2755975A1 (fr) 1998-05-22
HUP9904500A3 (en) 2002-01-28
JP2001506488A (ja) 2001-05-22

Similar Documents

Publication Publication Date Title
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
DE29603811U1 (de) Spannzwinge zur Einhandbedienung
DK0821690T3 (da) Nukleotidanaloger til behandling af virusinfektioner
DE69516835D1 (de) Kabel zur Ueberwachung des Schiefstandes von benachbarten Tragflächen
FR2755600B1 (fr) Instrumentation de pose d'une lame-agrafe pour osteotomie de soustraction pour le traitement d'une gonarthrose
DK0743366T3 (da) Påvisning af Listeria ved hjælp af rekombinante bakteriofager
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
HUP9902710A3 (en) Recombinant swinepox virus
DK0930091T3 (da) Fremgangsmåde til behandling af röggasser
FR2755975B1 (fr) Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
ITMI951010A0 (it) Mattone refrattario forato cilindrico
NO984602L (no) FremgangsmÕte ved pÕvisning av prion-medierte sykdommer
FR11C0050I2 (fr) Virus myxomateux recombinant
NO991158L (no) FremgangsmÕte for behandling av amyotrofisk lateralsklerose
DE59702259D1 (de) Vorrichtung zur diskontinuierlichen zubereitung von teigwaren
IT1275895B1 (it) Mattone refrattario
FR2749512B1 (fr) Utilisation de l'acetyl dl leucine pour le traitement des tremblements
FR2716760B1 (fr) Convertisseur analogique-numérique du type SIGMADELTA de degré élevé.
AU7154596A (en) Virus protein purification from virosomes
FR2746274B1 (fr) Ensemble de cinq formes pour des elements mobiliers
DK1122245T3 (da) 2-Aminobenzoxazinoner til behandling af virale infektioner
AU1633097A (en) DNA-based methods for the detection of Phytophthora species
BR7600466U (pt) Do arco de serra
IL118651A0 (en) Composition for the treatment of viral infections
KR950025002U (ko) 트랜스퍼 크레인의 주행각도 고정용 휠요오크(wheelyoke)

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse